Health knowledge made personal
|
After much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class, and that R&D resources for ViiV Healthcare should prioritize efforts to identify compounds that further HIV treatment. We remain committed to exploring candidates that will advance HIV treatment and contribute to improving outcomes for people living with HIV. Please don’t hesitate to reach out to me directly if you have any questions regarding this announcement. Kind regards, Marc Meachem | Director, External Affairs |
Write a comment:
|
Dear HIV Community Writer,